Literature DB >> 1895307

Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.

A Matsuda1, Y Nakajima, A Azuma, M Tanaka, T Sasaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1895307     DOI： 10.1021/jm00113a034

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  21 in total

Review 1.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

Authors:  Xiaojun Liu; Yaqing Wang; Sherri Benaissa; Akira Matsuda; Hagop Kantarjian; Zeev Estrov; William Plunkett
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

3.  Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Authors:  Xiaojun Liu; Yingjun Jiang; Billie Nowak; Bethany Qiang; Nancy Cheng; Yuling Chen; William Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-30       Impact factor: 3.333

Review 4.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

5.  Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

Authors:  S R Green; A K Choudhary; I N Fleming
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

6.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Authors:  Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Selina Luger; Parameswaran Venugopal; Lori Maness; Meir Wetzler; Steven Coutre; Wendy Stock; David Claxton; Stuart L Goldberg; Martha Arellano; Stephen A Strickland; Karen Seiter; Gary Schiller; Elias Jabbour; Judy Chiao; William Plunkett
Journal:  Lancet Oncol       Date:  2012-10-15       Impact factor: 41.316

7.  Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

Authors:  Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Robert Westwood; Simon R Green; Judy H Chiao; Patricia A Boone; Jorge Cortes; William Plunkett
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.

Authors:  Therese Triemer; Alessandra Messikommer; Stella M K Glasauer; Jawad Alzeer; Miriam H Paulisch; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

Review 9.  New drugs in acute myeloid leukemia.

Authors:  T M Kadia; F Ravandi; J Cortes; H Kantarjian
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

Review 10.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.